Skip to content

to study the effect of preservative free drug- eye drop to reduce pain in patients undergoing laser eye surgery to correct refractive errors

A study of the efficacy of topical preservative free ketorolac tromethamine ophthalmic solution 0.45% in reducing post operative pain in patients undergoing alcohol assisted photo refractive keratectomy

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2016/01/006536
Enrollment
50
Registered
2016-01-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- myopia , astigmatism refractive error

Interventions

Intervention1: topical preservative free ketorolac tromethamine ophthalmic solution 0.45%: patients will be instilled with the the above drug before surgery and then pain scores will be assessed at da

Sponsors

Nethradhama super speciality eye hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Spherical equivalent from -1 to -6 D. Stable refraction at least for the previous 1 year. Soft Contact lenses will have to be discontinued for minimum 1 week and rigid gas permeable contact lens discontinued for minimum 3 weeks before the baseline measurement

Exclusion criteria

Exclusion criteria: 1. Age less than 21 years and more than 40 years. 2. Evidence of lid diseases like meibomian gland dysfunction. 3. Anterior segment pathologies of the cornea like corneal dystrophy, corneal scars, keratitis, topographic evidence of keratoconus. Residual, recurrent or active ocular disease such as uveitis, severe dry eyes, severe allergic eye disease, glaucoma, visually significant cataract. 4. Retinal pathologies like diabetic retinopathy and retinal dystrophies. 5. Progressive or unstable myopia and/or irregular astigmatism. 6. Previous intraocular or corneal surgery. 7. Ocular medications being used like antiglaucoma medications. 8. Systemically immunocompromised. 9. Pregnant or nursing women

Design outcomes

Primary

MeasureTime frame
pain scoresTimepoint: day1,3,5

Secondary

MeasureTime frame
eye discomfortTimepoint: day1,3,5

Countries

India

Contacts

Public ContactDr Savio Pereira

NETHRADHAMA SUPERSPECIALITY EYE HOSPITAL

dr.savio.pereira@gmail.com09869921301

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026